Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Midkine-A potential therapeutic target in melanoma

    Research output: Contribution to journalComment/debateResearchpeer-review

View graph of relations

PURPOSE: Adoptive cell transfer therapy (ACT) based on autologous tumor-infiltrating lymphocytes (TIL) has achieved impressive clinical results in several phase I and II trials performed outside of Europe. Although transient, the toxicities associated with high-dose (HD) bolus IL2 classically administered together with TILs are severe. To further scrutinize whether similar results can be achieved with lower doses of IL2, we have carried out a phase I/II trial of TIL transfer after classical lymphodepleting chemotherapy followed by an attenuated IL2 regimen.

EXPERIMENTAL DESIGN: Twenty-five patients with progressive treatment-refractory metastatic melanoma, good clinical performance, age < 70 years, and at least one resectable metastasis were eligible. TIL infusion was preceded by standard lymphodepleting chemotherapy and followed by attenuated doses of IL2 administered in an intravenous, continuous decrescendo regimen ( Identifier: NCT00937625).

RESULTS: Classical IL2-related toxicities were observed but patients were manageable in a general oncology ward without the need for intervention from the intensive care unit. RECIST 1.0 evaluation displayed three complete responses and seven partial responses (ORR 42%). Median overall survival was 21.8 months. Tumor regression was associated with a higher absolute number of infused tumor-reactive T cells. Moreover, induction and persistence of antimelanoma T-cell responses in the peripheral blood was strongly correlated to clinical response to treatment.

CONCLUSIONS: TIL-ACT with a reduced IL2 decrescendo regimen results in long-lasting complete responses in patients with treatment-refractory melanoma. Larger randomized trials are needed to elucidate whether clinical efficacy is comparable with TIL-ACT followed by HD bolus IL2. Clin Cancer Res; 22(15); 3734-45. ©2016 AACR.

Original languageEnglish
JournalClinical Cancer Research
Issue number15
Pages (from-to)3734-45
Number of pages12
Publication statusPublished - 1 Aug 2016

    Research areas

  • Journal Article

ID: 48959262